This inventor holds 8 USPTO granted patents and 5 published patent applications and 3 EPO patents. Top assignee: Norlase Aps. Active years: 2021-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2026
Title: Innovations by Greg Fava in Ophthalmic Treatment
Introduction
Greg Fava is an accomplished inventor based in Redwood City, CA (US). He has made significant contributions to the field of ophthalmic treatment, holding a total of 8 patents. His work focuses on developing advanced technologies that enhance the effectiveness of eye treatments.
Latest Patents
One of Greg Fava's latest patents is the "Apparatus for Photothermal Ophthalmic Treatment." This innovative apparatus is designed for photocoagulation or photo-thermal stimulation. It includes a diagnostic instrument that emits illumination light towards a target area and receives light from that area for magnified viewing. The apparatus features an adapter unit with a housing that can be detachably mounted to the diagnostic instrument. It contains a treatment direct diode laser that emits light suitable for photothermal ophthalmic treatment within the wavelength range of 480 to 632 nm.
Another notable patent is the "Body Mounted Laser Indirect Ophthalmoscope (LIO) System." This system allows for the delivery of laser energy into a patient's eye through a wearable assembly. The assembly secures a control module, laser module, and power module to the user's body. The control module receives activation signals and parameter information from a mobile computing device, enabling precise control of the emitted laser energy.
Career Highlights
Greg Fava is currently associated with Norlase Aps, where he continues to innovate in the field of ophthalmology. His work has been instrumental in developing technologies that improve patient outcomes and streamline treatment processes.
Collaborations
Throughout his career, Greg has collaborated with notable colleagues, including Peter Skovgaard and Thomas Buss. These partnerships have fostered a creative environment that encourages the development of groundbreaking solutions in ophthalmic care.
Conclusion
Greg Fava's contributions to ophthalmic treatment through his innovative patents demonstrate his commitment to advancing medical technology. His work not only enhances treatment efficacy but also improves the overall patient experience.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile